Supervisory board

  1. Supervisory Board

Hubert Birner, PhD

Chairman of the Supervisory Board

Dr. Birner, Managing Partner, Montreal and Munich, is responsible for TVM Capital Life Science’s overall investment strategy and fund operations in North America and Europe. Dr. Birner joined TVM Capital in 2000 as an investment manager. He currently serves as Chairman of the board of directors of ...

... Noxxon Pharma N.V., SpePharm Holdings BV, leon nanodrugs GmbH, Argos Therapeutics and AL-S Pharma AG. He is also a member of the board of directors of Proteon Therapeutics Inc. and Acer Therapeutics Inc. Dr. Birner previously served on the board of directors of Horizon Pharma, Inc., Bioxell SA, Evotec AG, Probiodrug AG and Jerini AG. Prior to his current tenure, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca Agrochemicals. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development.

Before starting his professional career in business, he earned substantial academic merits, including a position as Assistant Professor for biochemistry at the Ludwig-Maximilian-University (LMU), following his summa cum laude doctoral degree in biochemistry at LMU; his doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Dr. Birner also holds an MBA from Harvard Business School.

Christoph Ehlers, LLM

Member of the Supervisory Board

Christoph is a German lawyer who obtained his degrees from the University of Konstanz, Germany, and the University of San Diego, USA. From 1983 to 1997, he held various investment and management positions at Commerzbank AG, Germany’s second largest private bank.

In 1997, Christoph started his own businesses working as a business angel developing technology driven companies, particularly in the Life Science sector. Under his leadership, numerous German companies has thrived to success. Apart from his involvement in the technological sector, Christoph is owner of Equicore Beteiligungs GmbH and founder and substantial shareholder of the Freiburger Vermögensmanagement GmbH (one of the leading private German portfolio management companies). He is also the co-founder and board member of one of the leading German economic and political think tanks, the "Stiftung Ordnungspolitik – Centrum für Europäische Politik", located in Freiburg. In addition, he is a member of various consulting boards.

Christoph has been one of the major and initial shareholders of CENTOGENE since 2008. In the initial years, he served the company as Managing Director. In 2014, Christoph became a member of CENTOGENE’s Supervisory Board focusing on the strategic orientation and development of the company.

Holger Friedrich

Member of the Supervisory Board

Holger has more than 25 years of experience in the IT industry. His focus is on software engineering and IT architecture management. Holger holds several leadership positions in leading institutions, including partner of a global management consulting firm and as an ...

... executive board member in several technology firms. He served as chairman of SPM Technolgies (acquired by SAP), was Partner at McKinsey and Board member at Software AG. Besides that, Holger was executive board member of CORE, a think tank for technologies in the financial services industry.

Jacob Kaluski, M.Sc. in Pharmacy

Member of the Supervisory Board

Jacob has more than 30 years of experience gained working in the pharmaceutical industry, focusing on international marketing and drug development/clinical trials. He has held several leadership positions within a leading pharmaceutical and ...

biotechnology company, including Vice President and Business Manager for growth hormone.

Jacob served in numerous other high-level positions at prominent pharmaceutical companies and was co-founder of TKT-Europe-5S, which launched the first orphan drug in Europe.

Guido Prehn

Member of the Supervisory Board

Guido has over 15 years of experience in the private equity industry. After several years in the investment banking department of Merrill Lynch, Guido gathered international investing experience at TPG Capital and Allianz Capital Partners.

In 2008 he built Deutsche Private Equity as the preeminent growth private equity platform for Mittelstand companies in the German speaking region. Ever since, he has supported numerous fast growing SMEs as an investor and board member.

Guido studied business administration at the European Business School, Oestrich-Winkel, De Paul University Chicago and Universidad Argentina de la Empresa, Buenos Aires.

Eric Souetre, MD

Member of the Supervisory Board

Eric has an extensive track record in the Lifescience and Biotech industry for the past decades. He initiated his career in medical research at the National Institute of Health (USA), being a former Assistant Professor of Paris Medical University.

He holds a PhD in Neurosciences by the Marseille University and a Medical Degree (MD) by the Medical University of Nice. He founded Benefit, a research and consulting company in 1990, that expanded rapidly to over six European countries and Canada before being acquired by Quintiles Inc. (USA) in 1995. As board member, Eric then took over worldwide responsibility in consulting for Quintiles Inc. and remained as a board member for several years.

In 2003, he co-founded Labco, and led the company to a European leadership as chairman and CEO until late 2010. Eric then remained as active board member, especially involved into the selling of Labco to Cinven in 2015.

Daniel Parera, MD

Member of the Supervisory Board

Daniel joined the TVM Capital Life Science team as Executive-in-Residence based in Munich in September 2016. He is responsible for deal sourcing, deal monitoring as well as transaction advisory. He currently serves as a member of the Board of Directors at ...

... MicrobeDx, Inc. Los Angeles, CA, and is an observer to the Board of Directors at Mediti Pharma, Inc. Montreal, QC.

Daniel joined TVM from Novartis, where he spent 12 years in three Divisions including Pharma in Basel, Switzerland, Vaccines & Diagnostics in Emeryville, CA, USA and Sandoz (Generics / Biopharmaceuticals) in Holzkirchen / Munich, Germany. He held various line function roles spanning from Research to Sales across the three businesses including Global Franchise Head Strategic Marketing for Immunology & Infectious Diseases and Global Head Marketing Transplantation in Pharma, Global Head of Development, Diagnostics and Global Head New Product & Portfolio Strategy Biopharmaceuticals at Sandoz.

He oversaw and was a team member for multiple collaborations, licensing deals and acquisitions from academic to multi-billion dollar transactions, world-wide commercial launches and FDA / EMA / CFDA / ANVISA registrations with respective clinical trials. His therapeutic disease area expertise includes Oncology/Hematology, Immunology (including Rheumatology, Dermatology, Gastroenterology), Infectious Diseases (Virology and Bacteriology), Solid Organ Transplantation and Nephrology. Prior to Novartis he was at McKinsey & Company, Inc. e.g., implementing DRGs and disease management programs for statutory and private health insurance companies, leading a turnaround case for an acute specialty hospital. He was also a juror and coach at the German Science 4 Life Venture Cup for 7 years from inception.

He is an MD from Johannes-Gutenberg-University Mainz, Germany with clinical training in Germany, Switzerland and the USA (UC Davis Medical Center, Sacramento, CA) and was a scientific co-worker at the Institute for Occupational, Social and Environmental Medicine in Mainz for several years. German-Indonesian, with wife and two daughters, he is a retired tennis and soccer league player. Now an active sailor he is also the Chairman of the Board for a growing Waldorf School south of Munich.

Michael Schlenk, MBA

Member of the Supervisory Board

Michael Schlenk earned a Diplom-Kaufmann degree from University Hamburg, Germany, and an MBA from University Bradford Management Centre, United Kingdom. After 6 years as a management consultant in the area of technology transfer, Michael Schlenk worked more than 20 years in the Life Science industry.

During his international career, he worked and lived in more than 10 countries. He held positions as strategic consultant, marketing manager, area manager, general manager and president of subsidaries of Novartis and Abbott. Before joining CENTOGENE, Michael was CEO of Berlin based Biotechnology company ProBioGen AG for 7 years. He led the company to sustained profitability and prepared it for the trade sale. Under his leadership, the organisation achieved numerous awards for fast growth and technological excellence: Deloitte Fast Forward Award (2 times), Step Award (FAZ German newspaper), BMBF and Peta. In 2010, ProBioGen AG was sold successfully to a leading Egyptian Pharma company.

Since 2003, Michael develops and invests as a business angel in young IT and Life Science companies. He is a member of various supervisory boards. In January 2011, Michael has invested, became shareholder and was designated Chief Executive Officer (CEO) of CENTOGENE.

Effective June 1, 2014, Michael handed over the CEO position to founder Arndt Rolfs. As member of the Supervisory Board and one of the main major shareholders, Michael will continue his support for CENTOGENE with his network and strategic understanding.